Adam Gurwin
Overview
Explore the profile of Adam Gurwin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
37
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Karwacki J, Mioskowska A, Tomecka P, Maczka K, Gurwin A, Kobylanski M, et al.
Int Urol Nephrol
. 2025 Mar;
PMID: 40088356
Purpose: This study aimed to evaluate the impact of metastatic lymph nodes (LNs) outside the extended pelvic lymph node dissection (ePLND) template on oncological outcomes, staging, grading, and concomitant parameters...
2.
Karwacki J, Stodolak M, Dlubak A, Nowak L, Gurwin A, Kowalczyk K, et al.
Eur Urol Open Sci
. 2024 Oct;
69:112-126.
PMID: 39430411
Background And Objective: Lymphovascular invasion (LVI) is a significant histopathological feature in prostate cancer (PCa) associated with higher risk of biochemical recurrence (BCR) and other adverse outcomes. Our aim was...
3.
Gurwin A, Karwacki J, Dorochowicz M, Kowalczyk K, Nowak L, Jedrzejuk D, et al.
J Clin Med
. 2024 Sep;
13(17).
PMID: 39274339
This study assessed the topography and lateralization of lymph node (LN) metastases in muscle-invasive bladder cancer (MIBC) patients using super-extended pelvic lymph node dissection (sePLND) with sentinel lymph node dissection...
4.
Kaczmarek K, Malkiewicz B, Gurwin A, Krawczyk W, Skonieczna-Zydecka K, Leminski A
J Clin Med
. 2024 Apr;
13(7).
PMID: 38610718
Neutrophil-to-lymphocyte ratio (NLR), a widely assessed biomarker in most common diseases, is typically evaluated before treatment initiation. However, data on NLR in the post-treatment setting is limited. Therefore, we assessed...
5.
Karwacki J, Gurwin A, Jaworski A, Jarocki M, Stodolak M, Dlubak A, et al.
Cancers (Basel)
. 2024 Mar;
16(5).
PMID: 38473287
Background: Lymphovascular invasion (LVI) is a vital but often overlooked prognostic factor in prostate cancer. As debates on lymphadenectomy's overtreatment emerge, understanding LVI laterality gains importance. This study pioneers the...
6.
Kielb P, Kaczorowski M, Kowalczyk K, Piotrowska A, Nowak L, Krajewski W, et al.
Front Oncol
. 2023 Oct;
13:1265788.
PMID: 37790749
Introduction: Prostate cancer (PCa) is the second most commonly diagnosed cancer in men worldwide. Lymph node metastasis is a poor prognostic factor for PCa. Previous studies have found that Golgi...
7.
Kielb P, Kowalczyk K, Gurwin A, Nowak L, Krajewski W, Sosnowski R, et al.
Biomedicines
. 2023 Jun;
11(6).
PMID: 37371647
Prostate cancer (PCa) is the second most frequently diagnosed cancer in men. Despite the significant progress in cancer diagnosis and treatment over the last few years, the approach to disease...
8.
Malkiewicz B, Jedrzejuk D, Gurwin A, Wilk K, Knecht-Gurwin K, Kielb P, et al.
J Clin Med
. 2023 May;
12(9).
PMID: 37176533
Background: The optimal limits of the bilateral pelvic lymph node dissection (PLND) template in bladder cancer treatment remain controversial. This study aimed to investigate whether radio-guided sentinel node (SLN) detection...
9.
Kaczmarek K, Leminski A, Malkiewicz B, Gurwin A, Lisinski J, Slojewski M
J Clin Med
. 2023 Feb;
12(4).
PMID: 36835795
There is a well-documented problem of inferior outcome of muscle-invasive bladder cancer (MIBC) after radical cystectomy (RC) in women. However, previous studies were conducted before neoadjuvant chemotherapy (NAC) was widely...
10.
Malkiewicz B, Gurwin A, Karwacki J, Nagi K, Knecht-Gurwin K, Hober K, et al.
Cancers (Basel)
. 2022 Nov;
14(21).
PMID: 36358705
The purpose of this review is to present the current knowledge about the diagnostic and treatment options for bladder cancer (BCa) patients with clinically positive lymph nodes (cN+). This review...